Browsing by Author "Alvarado-Ibarra, M"

Filter results by typing the first few letters
Now showing 1 - 2 of 2
  • No Thumbnail Available
    Publication
    Treating Acute Leukemia During the COVID-19 Pandemic in an Environment With Limited Resources: A Multicenter Experience in Four Latin American Countries
    (American Society of Clinical Oncology, 2021) Demichelis-Gómez, R; Alvarado-Ibarra, M; Vasquez-Chávez, J; Delgado-López, N; Gómez-Cortés, C; Espinosa-Bautista, K; Cooke-Tapia, A; Milán-Salvatierra, A; Gómez-De León, A; Lee-Tsai, YL; Rosales-López, D; Cabrera-García, Á; Amador-Medina, F; Córdoba-Ramírez, A; Murrieta-Álvarez, I; Solís-Poblano, JC; Apodaca-Chávez, E; Rangel-Patiño, J; Álvarez-Vera, JL; Arana-Luna, L; De la Peña-Celaya, JA; Espitia-Ríos, ME; Hernández-Ruiz, E; Pérez-Zúñiga, JM; Peña-López, E; González-Rivera, R; García-Leyva, MF; Tejeda-Romero, M; Cruz-Rico, J; Balderas-Delgado, C; Ruíz-Argüelles, GJ; Gómez-Almaguer, D
    Purpose: The COVID-19 pandemic is a colossal challenge for global health; nonetheless, specific subgroups face considerably higher risks for infection and mortality. Among patients with malignant diseases, those with hematologic neoplasms are at a higher risk for poor outcomes. The objective of this study was to register treatment modifications associated with the COVID-19 pandemic and their short-term consequences in Latin America.Methods: Multicenter, prospective, observational, cohort study including patients older than 14 years from 14 centers in four countries (Mexico, Peru, Guatemala, and Panama) who had a confirmed diagnosis of acute leukemia, and who were undergoing active treatment since the first COVID-19 case in each country until the cutoff on July 15, 2020.Results: We recruited 635 patients. Treatment modifications because of the COVID-19 pandemic were reported in 40.8% of cases. The main reason for such modifications was logistic issues (55.0%) and the most frequent modification was chemotherapy delay (42.0%). A total of 13.1% patients developed COVID-19 disease, with a mortality of 37.7%. Several factors were identified as independently associated with mortality, including a diagnosis of acute myeloid leukemia (odds ratio 2.38 [95% CI, 1.47 to 3.84]; P < .001), while the use of telemedicine was identified as a protective factor (odds ratio 0.36 [95% CI, 0.18 to 0.82]; P = .014). Conclusion: These results highlight the collateral damage of COVID-19 in oncology patients.
  • Thumbnail Image
    Publication
    Treating Acute Leukemia During the COVID-19 Pandemic in an Environment With Limited Resources: A Multicenter Experience in Four Latin American Countries
    (American Society of Clinical Oncology, 2021) Demichelis-Gómez, R; Alvarado-Ibarra, M; Vasquez-Chávez, J; Delgado-López, N; Gómez-Cortés, C; Espinosa-Bautista, K; Cooke-Tapia, A; Milán-Salvatierra, A; Gómez-De León, A; Lee-Tsai, YL; Rosales-López, D; Cabrera-García, Á; Amador-Medina, F; Córdoba-Ramírez, A; Murrieta-Álvarez, I; Solís-Poblano, JC; Apodaca-Chávez, E; Rangel-Patiño, J; Álvarez-Vera, JL; Arana-Luna, L; De la Peña-Celaya, JA; Espitia-Ríos, ME; Hernández-Ruiz, E; Pérez-Zúñiga, JM; Peña-López, E; González-Rivera, R; García-Leyva, MF; Tejeda-Romero, M; Cruz-Rico, J; Balderas-Delgado, C; Ruíz-Argüelles, GJ; Gómez-Almaguer, D
    Purpose: The COVID-19 pandemic is a colossal challenge for global health; nonetheless, specific subgroups face considerably higher risks for infection and mortality. Among patients with malignant diseases, those with hematologic neoplasms are at a higher risk for poor outcomes. The objective of this study was to register treatment modifications associated with the COVID-19 pandemic and their short-term consequences in Latin America. Methods: Multicenter, prospective, observational, cohort study including patients older than 14 years from 14 centers in four countries (Mexico, Peru, Guatemala, and Panama) who had a confirmed diagnosis of acute leukemia, and who were undergoing active treatment since the first COVID-19 case in each country until the cutoff on July 15, 2020. Results: We recruited 635 patients. Treatment modifications because of the COVID-19 pandemic were reported in 40.8% of cases. The main reason for such modifications was logistic issues (55.0%) and the most frequent modification was chemotherapy delay (42.0%). A total of 13.1% patients developed COVID-19 disease, with a mortality of 37.7%. Several factors were identified as independently associated with mortality, including a diagnosis of acute myeloid leukemia (odds ratio 2.38 [95% CI, 1.47 to 3.84]; P < .001), while the use of telemedicine was identified as a protective factor (odds ratio 0.36 [95% CI, 0.18 to 0.82]; P = .014). Conclusion: These results highlight the collateral damage of COVID-19 in oncology patients.